Terveydenhuollon laitteet, lääkkeet ja hygieniatuotteet:…

Tilanne teille

Kolme asiaa, jotka kannattaa punnita ennen kuin käytätte aikaa tarjoukseen

AikaTarjousaika on päättynytMääräpäivä oli 24.11.2023
KilpailuVähäinen kilpailu≈ 1,5 tarjousta keskimäärin alalla terveydenhuollon laitteet, lääkkeet ja hygieniatuotteet, CPV 3369 koko Suomessa
Kuka yleensä voittaaEi selvää suosikkia3 eri voittajaa 3 viimeisimmässä sopimuksessa

Yritysprofiilin avulla näytämme myös, kuinka hyvin hankinta sopii teille. Luo tili – kokeile maksutta 14 päivää

Tarjoustaulu on luettelonne hankinnoista, joita harkitsette tai joiden parissa työskentelette, vaiheittain ensimmäisestä vilkaisusta jätettyyn tarjoukseen.

Lisää tarjoustauluun Tilaa hakuvahti vastaavista hankinnoista Lähetä kollegalle

Kilpailutilanne

Kuka on voittanut hankintayksikön sopimukset ja montako tarjousta yleensä jätetään

Hankintayksikön viimeisimmät vastaavat sopimukset

Päätös	Voittaja ja sopimus	Tarjouksia	Arvo
30.3.2026	Roche Diagnostics OyAnalyysilaitteiston (Sysmex verenkuva-analysaattori XN-1000) reagenssit ja huoltosopimus120 000 €	–	120 000 €
26.2.2026	Voittajaa ei julkaistuAzithromycin oral suspension 40 mg/ml - SUSPENDED	–	–
22.12.2025	Voittajaa ei julkaistuAzithromycin oral suspension 40 mg/ml - SUSPENDED	–	–
16.12.2025	BioNordika OyWGS kirjastokitit269 000 €	–	269 000 €
18.11.2025	MIP Pharma Holding GmbHClindamycin 150 mg/ml (4ml per vial/ampoule)618 000 €	–	618 000 €
17.11.2025	Voittajaa ei julkaistuNextera XT Library Preparation Kit	–	–

Näin monta tarjousta yleensä jätetään

Vähäinen kilpailu. Vastaavat hankinnat saavat keskimäärin 1,5 tarjousta.

Keskiarvo koskee alaa terveydenhuollon laitteet, lääkkeet ja hygieniatuotteet, CPV 3369 koko Suomessa viimeisten kolmen vuoden ajalta.

Tarjousten määrä hankintapäätöstä kohden

Tarjouksia keskimäärin: 1,5
Sai vain yhden tarjouksen: 78 %
Sopimusarvon mediaani: 398 500 €
Pk-yritysten voittamia: –

Todennäköiset kilpailijat

Triolab Oy on voittanut eniten sopimuksia alalla terveydenhuollon laitteet, lääkkeet ja hygieniatuotteet, CPV 3369 koko Suomessa: 6 viimeisten kolmen vuoden aikana, arvoltaan 2,2 milj. €.

+ 7 muuta Pro-tasolla, voittojen määrä ja sopimusarvo mukanaKokeile Pro-tasoa maksutta

Kilpailu juuri alueella Uusimaa (hankintayksikön maakunta) verrattuna koko SuomeenKokeile Pro-tasoa maksutta

LÄHDETED23 hankintapäätöstä, joissa on ilmoitettu tarjousten määrä, kolme vuottaArviokeskiarvot ja osuudet laskenut Tarjoustilanne

Mitä hankitaan

Ilmoituksen teksti sellaisenaan

Finnish Institute for Health and Welfare, later referred to as THL, request your tender for Antidotes and poisoning medical products to the rescEU project. The Scope of procurement is described in more detail in Annex 1. The procurement is divided in thirteen (13) lots. Tender may be submitted for one or several lots. - LOT 1: Dimercaptopropane sulfonate (DMPS) 100 mg tablets/capsules - LOT 2: Prussian blue, i.e. Iron(III) hexacyanoferrate(II) 500 mg tablets/capsules - LOT 3: Succimer (Dimercaptosuccinic acid, DMSA) 200 mg tablets/capsules - LOT 4: Dimercaptopropane sulfonate (DMPS) 50 mg/ml (5 ml per vial/ampoule) - LOT 5: Calcium trisodium pentetate (Ca-DTPA) 1 g / 5 ml (5 ml per vial/ampoule) - LOT 6: Zinc trinatrium pentetate (Zn-DTPA) 1055 mg / 5 ml (5 ml per vial/ampoule) - LOT 7: Obidoxime 250 mg/ml (1 ml per vial/ampoule) - LOT 8: Pralidoxime 2 g / 100 ml (100 ml per vial/ampoule) - LOT 9: Hydroxocobalamin 5 g (5 g per vial/ampoule) - LOT 10: Fomepizole 5 mg/ml (20 ml per vial/ampoule) - LOT 11: Calcium edetate (Ca-EDTA) 50 mg/ml (10 ml per vial/ampoule) - LOT 12: Calcium gluconate 100 mg/ml (10 ml per vial/ampoule) - LOT 13: Silver sulfadiazine 10 mg/g (50 g - 100 g per tube/container) The minimum requirements for the articles is described in Annex 1.1. The contract will be awarded to one Supplier for each lot based on a comparison of tenders. Tender that is economically the most advantageous will win the competition. The contract period shall enter into force once the contract has been signed by contracting parties and expires when all contractual duties of the contract have been performed. Estimated quantity for the product in described in Annex 6 (restricted to security classification level IV, TL IV). Please note that all times given in the Call for Tender refer to local time in Finland. Call for Tenders, Annexes: Annex 1 Scope of the procurement Annex 1.1 Minimum requirements Annex 2 Contract Annex 3 Security annex Annex 4 Description of the Handi service Annex 5 JYSE 2014 SUPPLIES (updated version of April 2022) Annex 6 Estimated quantity (restricted, TL IV) Annex 7 Confidentiality commitment Please note that the numbering of the annexes differs between the Contract and the Call for Tenders.

Näytä koko kuvaus

Hankinta on jaettu 13 osaan. Tarjouksen voi jättää enintään 13 osaan.

LOT 1: Dimercaptopropane sulfonate (DMPS) 100 mg tablets/capsules
The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Dimercaptopropane sulfonate (DMPS) 100 mg - Oral solid dosage forms - Active pharmaceutical ingredient: Dimercaptopropane sulfonate (DMPS) - Strength: 100 mg - Pharmaceutical form: tablets/capsules. The minimum requirements of the article is described in more detail in Annex 1.1. The…
LOT 2: Prussian blue, i.e. Iron(III) hexacyanoferrate(II) 500 mg tablets/capsules
The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Prussian blue, i.e. Iron(III) hexacyanoferrate(II) 500 mg tablets/capsules - Oral solid dosage forms - Active pharmaceutical ingredient: Prussian blue, i.e. Iron(III) hexacyanoferrate(II) - Strength: 500 mg - Pharmaceutical form: tablets/capsules. The minimum requirements of the artic…
LOT 3: Succimer (Dimercaptosuccinic acid, DMSA) 200 mg tablets/capsules
The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Succimer (Dimercaptosuccinic acid, DMSA) 200 mg tablets/capsules - Oral solid dosage forms - Active pharmaceutical ingredient: Succimer (Dimercaptosuccinic acid, DMSA) - Strength: 200 mg - Pharmaceutical form: tablets/capsules. The minimum requirements of the article is described in m…
LOT 4: Dimercaptopropane sulfonate (DMPS) 50 mg/ml (5 ml per vial/ampoule)
The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Dimercaptopropane sulfonate (DMPS) 50 mg/ml (5 ml per vial/ampoule) - Parenteral product (intravenous administration) - Active pharmaceutical ingredient: Dimercaptopropane sulfonate (DMPS) - Strength: 50 mg/ml - Container size: 5 ml per vial/ampoule. The minimum requirements of the ar…
LOT 5: Calcium trisodium pentetate (Ca-DTPA) 1 g / 5 ml (5 ml per vial/ampoule)
The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Calcium trisodium pentetate (Ca-DTPA) 1 g / 5 ml (5 ml per vial/ampoule) - Parenteral product (intravenous administration) - Active pharmaceutical ingredient: Calcium trisodium pentetate (Ca-DTPA) - Strength: 1 g / 5 ml - Container size: 5 ml per vial/ampoule. The minimum requirements…
LOT 6: Zinc trinatrium pentetate (Zn-DTPA) 1055 mg / 5 ml (5 ml per vial/ampoule)
The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Zinc trinatrium pentetate (Zn-DTPA) 1055 mg / 5 ml (5 ml per vial/ampoule) - Parenteral product (intravenous administration) - Active pharmaceutical ingredient: Zinc trinatrium pentetate (Zn-DTPA) - Strength: 1055 mg / 5 ml - Container size: 5 ml per vial/ampoule. The minimum requirem…
LOT 7: Obidoxime 250 mg/ml (1 ml per vial/ampoule)
The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Obidoxime 250 mg/ml (1 ml per vial/ampoule) - Parenteral product (intravenous administration) - Active pharmaceutical ingredient: Obidoxime - Strength: 250 mg/ml - Container size: 1 ml per vial/ampoule. The minimum requirements of the article is described in more detail in Annex 1.1.…
LOT 8: Pralidoxime 2 g / 100 ml (100 ml per vial/ampoule)
The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Pralidoxime 2 g / 100 ml (100 ml per vial/ampoule) - Parenteral product (intravenous administration) - Active pharmaceutical ingredient: Pralidoxime - Strength: 2 g / 100ml - Container size: 100 ml per vial/ampoule. The minimum requirements of the article is described in more detail i…
LOT 9: Hydroxocobalamin 5 g (5 g per vial/ampoule)
The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Hydroxocobalamin 5 g (5 g per vial/ampoule) - Parenteral product (intravenous administration) - Active pharmaceutical ingredient: Hydroxocobalamin - Strength: 5 g - Container size: 5 g per vial/ampoule. The minimum requirements of the article is described in more detail in Annex 1.1.…
LOT 10: Fomepizole 5 mg/ml (20 ml per vial/ampoule)
The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Fomepizole 5 mg/ml (20 ml per vial/ampoule) - Parenteral product (intravenous administration) - Active pharmaceutical ingredient: Fomepizole - Strength: 5 mg/ml - Container size: 20 ml per vial/ampoule. The minimum requirements of the article is described in more detail in Annex 1.1.…
LOT 11: Calcium edetate (Ca-EDTA) 50 mg/ml (10 ml per vial/ampoule)
The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Calcium edetate (Ca-EDTA) 50 mg/ml (10 ml per vial/ampoule) - Parenteral product (intravenous administration) - Active pharmaceutical ingredient: Calcium edetate (Ca-EDTA) - Strength: 50 mg/ml - Container size: 10 ml per vial/ampoule. The minimum requirements of the article is describ…
LOT 12: Calcium gluconate 100 mg/ml (10 ml per vial/ampoule)
The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Calcium gluconate 100 mg/ml (10 ml per vial/ampoule) - Parenteral product (intravenous administration) - Active pharmaceutical ingredient: Calcium gluconate - Strength: 100 mg/ml - Container size: 10 ml per vial/ampoule. The minimum requirements of the article is described in more det…
LOT 13: Silver sulfadiazine 10 mg/g (50 g - 100 g per tube/container)
The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Silver sulfadiazine 10 mg/g (50 g - 100 g per tube/container) - Cream on the skin for topical use - Active pharmaceutical ingredient: Silver sulfadiazine - Strength: 10 mg/g - Container size: 50 g - 100 g per tube/container. The minimum requirements of the article is described in more…

Sopimuskausi: 1,4 v
Menettely: Avoin menettelyKaikki yritykset voivat jättää tarjouksen suoraan.
Suorituspaikka: Ei ilmoitettu. Hankintayksikkö sijaitsee: Helsinki, Uusimaa
Toimiala: Terveydenhuollon laitteet, lääkkeet ja hygieniatuotteetCPV-koodi 33690000, EU:n koodi hankinnan kohteelle
Osat: 13, tarjous enintään 13 osaan
Sopimusmuoto: SopimusSopimus määrätystä toimituksesta.

Hankinnat

Markkinat

Tarjoustilanne

Antidotes and poisoning medical products / 2024-2025